Table 4– Demographic, epidemiological and clinical characteristics of 121 multidrug-resistant tuberculosis (TB) cases enrolled in the meta-analysis
TotalLNZ daily dose ≤600 mgLNZ daily dose >600 mgp-value
Male65/121 (53.7)40/72 (55.6)25/49 (51.0)0.62
Age at admission yrs32 (25–41)30.5 (22.5–41)33 (27–42)0.42
Country of birth
 Europe12/75 (16.0)2/45 (4.4)10/30 (33.3)0.0008
 Asia52/75 (69.3)37/45 (82.2)15/30 (50.0)0.003
 Africa6/75 (8.0)3/45 (6.7)3/30 (10.0)0.61
 Other geographical areas5/75 (6.7)3/45 (6.7)2/30 (6.7)
Migrant29/82 (35.4)9/45 (20.0)20/37 (54.1)0.001
HIV positive9/104 (8.7)0/55 (0.0)9/49 (18.4)0.0009
Previous exposure to anti-TB therapy >1 month93/121 (76.9)51/72 (70.8)42/49 (85.7)0.06
Number of times treated with anti-TB drugs for >1 month1 (0–4)1 (0–4)1 (0–3)0.81
Sputum-smear positive102/110 (92.7)66/72 (91.7)36/38 (94.7)0.56
Pulmonary TB116/120 (96.7)71/72 (98.6)45/48 (93.8)0.15
Extra-pulmonary TB12/95 (12.6)4/53 (7.6)8/42 (19.1)0.09
Radiological findings
 Cavitary lesions39/106 (36.8)21/69 (30.4)18/37 (48.7)0.06
 Bilateral pulmonary involvement with cavitary lesions40/106 (37.7)26/69 (37.7)14/37 (37.8)0.99
 Bilateral pulmonary involvement6/106 (5.7)5/69 (7.3)1/37 (2.7)0.33
 Non-cavitary unilateral pulmonary involvement21/106 (19.8)17/69 (24.6)4/37 (10.8)0.09
XDR-TB39/120 (32.5)25/71 (35.2)14/49 (28.6)0.45
Surgical treatment27/108 (25.0)12/72 (16.7)15/36 (41.7)0.005
Hospital stay days39 (15–82)37 (12–79)60 (19–159)0.37
  • Data are presented as n/N (%) or median (interquartile range), unless otherwise stated. LNZ: linezolid; XDR-TB: extensively drug-resistant TB.